aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 30.22% | -3.39% | |||
| Gross Profit | -30.22% | 3.39% | |||
| SG&A Expenses | 24.50% | 10.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.78% | -0.30% | |||
| Operating Income | -28.78% | 0.30% | |||
| Income Before Tax | -31.25% | 0.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.25% | 0.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 0.00% | |||
| Net Income | -31.26% | 0.58% | |||
| EBIT | -28.78% | 0.30% | |||
| EBITDA | -29.10% | 0.25% | |||
| EPS Basic | -25.92% | 4.86% | |||
| Normalized Basic EPS | -25.95% | 4.95% | |||
| EPS Diluted | -25.92% | 4.86% | |||
| Normalized Diluted EPS | -25.95% | 4.95% | |||
| Average Basic Shares Outstanding | 4.20% | 4.55% | |||
| Average Diluted Shares Outstanding | 4.20% | 4.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||